Step-Up HS
Brief summary
Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (anal/genital) regions. This study will assess how safe and effective upadacitinib is in treating adult and adolescent participants with moderate to severe HS who have failed to respond to or are intolerant of anti-tumor necrosis factor (TNF) therapy. Adverse events and change in disease activity will be assessed. Upadacitinib is an approved drug for ulcerative colitis, atopic dermatitis, rheumatoid arthritis, psoriatic arthritis, and axial spondylarthritis and is being developed for the treatment of HS. This study is "double-blinded", meaning that neither the trial participants nor the study doctors will know who will be given upadacitinib and who will be given placebo. This study is comprised of 3 periods. In Period 1, participants are randomized into 2 groups called treatment arms where each group receives a different treatment. There is a 1 in 2 chance that participants will be assigned to placebo. In Period 2, participants are placed into 6 different groups depending on their placement and results in Period 1. Period 3 is the long-term extension period where participants will continue treatment from Period 2. Approximately 1328 adult and adolescent participants diagnosed with HS will be enrolled in approximately 275 sites worldwide. Participants will receive oral tablets of upadacitinib or placebo once daily for 36 weeks in Period 1 and Period 2. Eligible participants from Period 1 and Period 2 will enter Period 3 and receive oral tablets of upadacitinib or placebo once daily for 68 weeks. Participants will be followed up for approximately 30 days. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular outpatient visits during the study. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.
Interventional study
- 1
- 2
- 3
- 4
Would you like to know more about this trial?
|
Please note, participation in the clinical trial is open to patients with the disease or condition under investigation. |
Age:
12 Years and older.
Inclusion Criteria:
- Diagnosis of HS for at least 6 months prior to Baseline, as determined by the
investigator (i.e., through medical history and interview of subject).
- Documented history of previous use of ≥ 1 TNF inhibitor for HS for at least 12 weeks
and/or 1 approved non-anti-TNF biologic therapy for HS for at least 16 weeks
characterized by inadequate response or for any duration characterized by
intolerance as determined by the investigator.
- Participant must have a total AN count of ≥ 5 at Baseline.
- HS lesions must be present in at least 2 distinct anatomic areas at Baseline.
- At least 1 anatomic area of HS involvement characterized as Hurley Stage II or
higher at Baseline.
- Draining fistula count of ≤ 20 at Baseline.
Exclusion Criteria:
- History of active skin disease other than HS that could interfere with the
assessment of HS, including skin infections (bacterial, fungal, or viral) requiring
systemic treatment within 4 weeks of the Baseline visit.
- Treatment with any investigational drug of chemical or biologic nature within a
minimum of 30 days or 5 half-lives (whichever is longer) prior to the first dose of
study drug or be currently enrolled in another interventional clinical study.
Investigational drugs are also prohibited during the study.
- Previous treatment with any cell-depleting therapies including but not limited to
anti-CD20 (e.g., rituximab) within 12 months prior to Baseline or until B cell count
returns to normal level or pre-treatment level.
- Use of prescription topical therapies (including topical antibiotics) that can also
be used to treat HS within 14 days prior to the Baseline visit.
- Received any systemic (including oral) antibiotic treatment for HS or any other
chronic inflammatory disorder within 14 days prior to the Baseline visit.
